Faricimab is a Monoclonal Antibody owned by F. Hoffmann-La Roche, and is involved in 20 clinical trials, of which 13 were completed, 6 are ongoing, and 1 is planned.
Faricimab is a bi-specific antibody acts as vascular endothelial growth factor A (VEGF-A) and angiopoietin 2 (Ang-2) inhibitor. VEGF-A is highly expressed in cancer cells and retina leading to the uncontrollable cell division and neovascularization. Angiopoietin-2 (Ang2) induces initiation of retinal neovascularization. Dual inhibition of ANG-2 and VEGF-A results in the suppression of cell division and inhibits angiogenesis.
The revenue for Faricimab is expected to reach a total of $45.6bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Faricimab NPV Report.
Faricimab is originated and owned by F. Hoffmann-La Roche.
Faricimab (Vabysmo) is a humanized bispecific immunoglobulin G1 (IgG1) antibody. It is formulated as solution for intravitreal route of administration. Vabysmo is indicated for the treatment of people with wet, or neovascular, age-related macular degeneration (AMD) and diabetic macular edema (DME).
Faricimab is under development for the treatment of diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, diabetic retinopathy, macular edema due to branch retinal vein occlusion, choroidal neovascularization secondary to age-related macular degeneration and wet age-related macular degeneration. The drug candidate is administered through intravitreal route. It is a new molecular entity (NME). RG-7716 is a bi-specific antibody developed with CrossMab technology to tightly bind VEGF-A on one arm and angiopoietin (Ang)-2 on the other arm.
F. Hoffmann-La Roche Overview
F. Hoffmann-La Roche (Roche) is a biotechnology company that develops drugs and diagnostics to treat major diseases. It provides medicines for the treatment of cancer, other auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. The company also offers in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management solutions. Roche conducts research to identify novel methods to prevent, diagnose, and treat diseases. The company offers its products and services to hospitals, commercial laboratories, healthcare professionals, researchers, and pharmacists. Together with its subsidiaries and partners, the company has operations in various countries. Roche is headquartered in Basel, Switzerland.
The company reported revenues of (Swiss Francs) CHF62,801 million for the fiscal year ended December 2021 (FY2021), an increase of 7.7% over FY2020. In FY2021, the company’s operating margin was 28.9%, compared to an operating margin of 31.8% in FY2020. In FY2021, the company recorded a net margin of 22.2%, compared to a net margin of 24.5% in FY2020.
Quick View – Faricimab
|Highest Development Stage|